Condition: Antisynthetase Syndrome · Rheumatoid Arthritis · Sponsor: The First Affiliated Hospital with Nanjing Medical University
A single-center, open-label dose-escalation design to evaluate the safety and efficacy of 3 infusions of anti CD19 CAR NK cells (KN5501), as well as the expansion and persistence of KN5501 in patients with refractory antisynthetase antibody syndrome (ASyS) and rheumatoid arthritis (RA); To evaluate the ability of KN5501 to clear CD19-positive B cells in patients to determine the feasibility of KN5501 for the treatment of refractory ASyS and or RA.
This description comes directly from the study's public registry record.
Wenfeng Tan, PhD, MD · 086 18061202878 · tanwenfeng@jsph.org.cn
Hanxiao You, PhD, MD · 086 18800181269 · youhanxiao@jsph.org.cn
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital with Nanjing Medical University | Nanjing, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06613490